{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:25Z","timestamp":1787020825228,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0255-4","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T15:14:59Z","timestamp":1458314099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Giorgio","family":"La Nasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Littera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Oppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Celeghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Caria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Porcella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carcassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,16]]},"reference":[{"key":"255_CR1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.hoc.2013.10.004","volume":"28","author":"C Diefenbach","year":"2014","unstructured":"Diefenbach C, Advani R. Customized targeted therapy in Hodgkin lymphoma: hype or hope? Hematol Oncol Clin North Am. 2014;28:105\u201322.","journal-title":"Hematol Oncol Clin North Am"},{"key":"255_CR2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"A Gallamini","year":"2014","unstructured":"Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography on Hodgkin lymphoma treatment outcome is confirmed using the 5-point scale interpretation criteria. Haematologica. 2014;99:1107\u201313.","journal-title":"Haematologica"},{"key":"255_CR3","first-page":"144","volume":"1","author":"DW Scott","year":"2014","unstructured":"Scott DW, Steidl C. The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling. ASH Education Book. 2014;1:144\u201350.","journal-title":"ASH Education Book"},{"key":"255_CR4","doi-asserted-by":"crossref","unstructured":"Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, et al. Immunological deregulation in classic Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2014; e2014039. doi: 10.4084\/MJHID.2014.039 .","DOI":"10.4084\/mjhid.2014.039"},{"key":"255_CR5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-642-12780-9_4","volume-title":"Hodgkin lymphoma: a comprehensive update on diagnostics and clinics","author":"L Visser","year":"2011","unstructured":"Visser L, Van den Berg A, Poppema S, Diepstra A. Microenvironment, cross-talk, and immune escape mechanisms. In: Engert A, Horning SJ, editors. Hodgkin lymphoma: a comprehensive update on diagnostics and clinics. Berlin: Springer Verlag; 2011. p. 49\u201358."},{"key":"255_CR6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/1535-7163.MCT-09-0327","volume":"8","author":"AK Purdy","year":"2009","unstructured":"Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol The. 2009;8:2211\u201320.","journal-title":"Cancer Biol The"},{"key":"255_CR7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.genom.7.080505.115726","volume":"7","author":"AA Bashirova","year":"2006","unstructured":"Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277\u2013300.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"255_CR8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1600-065X.2002.19004.x","volume":"190","author":"KC Hsu","year":"2002","unstructured":"Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev. 2002;190:40\u201352.","journal-title":"Immunol Rev"},{"key":"255_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1479-5876-4-44","volume":"4","author":"A Bontadini","year":"2006","unstructured":"Bontadini A, Testi M, Cuccia MC, Martinetti M, Carcassi C, Chiesa A, et al. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J Transl Med. 2006;4:44.","journal-title":"J Transl Med"},{"key":"255_CR10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri3370","volume":"13","author":"P Parham","year":"2013","unstructured":"Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol. 2013;13:133\u201344.","journal-title":"Nat Rev Immunol"},{"key":"255_CR11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4049\/jimmunol.178.1.235","volume":"178","author":"GM O\u2019Connor","year":"2007","unstructured":"O\u2019Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1\/S1 receptor on human NK cells. J Immunol. 2007;178:235\u201341.","journal-title":"J Immunol"},{"key":"255_CR12","doi-asserted-by":"crossref","unstructured":"Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201\u201314.\u115f","DOI":"10.1038\/nri1570"},{"key":"255_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","volume":"26","author":"D Marin","year":"2012","unstructured":"Marin D, Gabriel IH, Ahmad S, Foroni L, De Lavallade H, Clark R, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012;26:296\u2013302.","journal-title":"Leukemia"},{"key":"255_CR14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.humimm.2009.07.004","volume":"70","author":"M Bernal","year":"2009","unstructured":"Bernal M, Garrido P, Jim\u00e9nez P, Carretero R, Almagro M, L\u00f3pez P, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol. 2009;70:854\u20137.","journal-title":"Hum Immunol"},{"key":"255_CR15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1399-0039.2011.01721.x","volume":"78","author":"L Karabon","year":"2011","unstructured":"Karabon L, Jedynak A, Giebel S, Wo\u0142owiec D, Kielbinski M, Woszczyk D, et al. KIR\/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens. 2011;78:129\u201338.","journal-title":"Tissue Antigens"},{"key":"255_CR16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood-2010-10-313791","volume":"118","author":"Z Almalte","year":"2011","unstructured":"Almalte Z, Samarani S, Iannello A, Debbeche O, Duval M, Infante-Rivard C, et al. Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia. Blood. 2011;118:1323\u20138.","journal-title":"Blood"},{"key":"255_CR17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","volume":"41","author":"G La Nasa","year":"2013","unstructured":"La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, et al. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol. 2013;41:424\u201331.","journal-title":"Exp Hematol"},{"key":"255_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000406","volume":"2","author":"C Besson","year":"2007","unstructured":"Besson C, Roetynck S, Williams F, Orsi L, Amiel C, Lependeven C, et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin\u2019s lymphoma in a familial study. PLoS One. 2007;2, e406.","journal-title":"PLoS One"},{"key":"255_CR19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease: international prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med. 1998;339:1506\u201314.","journal-title":"N Engl J Med"},{"key":"255_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0198-8859(02)00373-7","volume":"63","author":"K Gagne","year":"2002","unstructured":"Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Human Immunol. 2002;63:271\u201380.","journal-title":"Human Immunol"},{"key":"255_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00251-002-0497-x","volume":"54","author":"M Yawata","year":"2002","unstructured":"Yawata M, Yawata N, McQueen KL, Cheng NW, Guethlein LA, Rajalingam R, et al. Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression. Immunogenetics. 2002;54:543\u201350.","journal-title":"Immunogenetics"},{"key":"255_CR22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2009.03208.x","volume":"129","author":"D Middleton","year":"2010","unstructured":"Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology. 2010;129:8\u201319.","journal-title":"Immunology"},{"key":"255_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hoc.2013.10.001","volume":"28","author":"AE Hay","year":"2014","unstructured":"Hay AE, Meyer RM. Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone. Hematol Oncol Clin North Am. 2014;28:49\u201363.","journal-title":"Hematol Oncol Clin North Am"},{"key":"255_CR24","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","volume":"120","author":"KL Tan","year":"2012","unstructured":"Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120:3280\u20137.","journal-title":"Blood"},{"key":"255_CR25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","volume":"31","author":"DW Scott","year":"2013","unstructured":"Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2013;31:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"255_CR26","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2013-02-484451","volume":"121","author":"RM Meyer","year":"2013","unstructured":"Meyer RM. EBV DNA: a Hodgkin lymphoma biomarker? Blood. 2013;121:3541\u20132.","journal-title":"Blood"},{"key":"255_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1593\/tlo.12142","volume":"5","author":"H Knecht","year":"2012","unstructured":"Knecht H, Kongruttanachok N, Sawan B, Brossard J, Pr\u00e9vost S, Turcotte E, et al. Three dimensional telomere signatures of Hodgkin- and Reed-Sternberg cells at diagnosis identify patients with poor response to conventional chemotherapy. Transl Oncol. 2012;5:269\u201377.","journal-title":"Transl Oncol"},{"key":"255_CR28","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","volume":"118","author":"DM Benson Jr","year":"2011","unstructured":"Benson Jr DM, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118:6387\u201391.","journal-title":"Blood"},{"key":"255_CR29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123:678\u201386.","journal-title":"Blood"},{"key":"255_CR30","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","volume":"120","author":"DM Benson Jr","year":"2012","unstructured":"Benson Jr DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma. Blood. 2012;120:4324\u201333.","journal-title":"Blood"},{"issue":"Suppl 1","key":"255_CR31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2011.10.033","volume":"18","author":"WJ Murphy","year":"2012","unstructured":"Murphy WJ, Parham P, Miller JS. NK cells, from bench to clinic. Biol Blood Marrow Transplant. 2012;18 Suppl 1:S2\u20137. doi: 10.1016\/j.bbmt.2011.10.033 .","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0255-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:37:07Z","timestamp":1498279027000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/9\/1\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0255-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,16]]},"article-number":"26"}}